Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...

LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® ...

Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...

LUND, Sweden, March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has issued a positive ...

The content of this evidence summary was up-to-date in February 2019. See summaries of product characteristics (SPCs), British national formulary (BNF), or the Medicines and Healthcare products ...

Camurus, a Swedish, science-led biopharmaceutical company, announced topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal (prolonged-release ...

LUND, Sweden, Sept. 21, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use, CHMP, has adopted a ...

LUND, Sweden , Dec. 18, 2020 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal &circledR ...

People currently on a methadone programme have to take the drug daily A drug used in a pilot scheme to help prisoners affected by heroin addiction is to be rolled out across Scotland. Buvidal acts as ...